|Bid||152.170 x 900|
|Ask||152.350 x 1000|
|Day's Range||145.50 - 153.02|
|52 Week Range||79.88 - 188.82|
|Beta (3Y Monthly)||3.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||200.13|
Planned U.S. commercial launch of ZULRESSO™ injection, if approved, on track for June 2019, based on PDUFA target date of March 19, 2019 and anticipated DEA schedulin
NEW YORK, NY / ACCESSWIRE / February 19, 2019 / SAGE Therapeutics, Inc. (NASDAQ: SAGE ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 19, 2019 at ...
An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.
Baker Bros., which was among the top 20 holders of the biotech stock at the end of September, sold its final 567,497 shares by the end of 2018, according to a regulatory filing this week. Baker Bros. didn’t immediately respond to a request for comment. To be sure, the New York-based hedge fund held just under half a million shares back in 2017 when Sage approached $100 per share after its lead asset saw success in another clinical trial.
SAGE Therapeutics Inc NASDAQ NMS:SAGEView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for SAGE with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 15. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding SAGE totaled $4.45 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on February 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 8,500 shares of its common stock, and 750 performance restricted stock units (PSUs) to two new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, February 19, 2019 at 8:00 a.m.
The continued need for new Parkinson's disease treatments drew attention this week, with one local gene therapy biotech striking a $165 million collaboration deal, while another companies' drug was rejected by the FDA.
HOUSTON, TX / ACCESSWIRE / January 24, 2019 / Healthcare is quickly being disrupted by artificial intelligence. In fact, AI is quickly proving it can spot warning signs of disease before we're even aware of it ourselves. "Artificial intelligence could also use the way we look to help us predict future disease.
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski, Ph.D., to the company’s board of directors. As Sage continues to advance its programs in development, adding an executive with Liz’s expertise in scaling businesses and launching products globally will be invaluable,” said Jeff Jonas, M.D., chief executive officer of Sage. “We are just as excited to announce that George Golumbeski will be joining our board.
Citron Research, the activist short-seller headed by Andrew Left, has dug up some nasty evidence against Ligand Pharmaceuticals Inc. (LGND). In a 23-page report, Citron accused the San Diego-based biopharmaceutical company of misleading investors, adding that its future revenue calculations are a "pipe dream." The short seller then slapped a $35 price target on the stock, implying 80% downside from the report’s publication date. After failing to successfully develop its own drugs, Ligand switched its business model to focus on collecting royalties and milestone payments from compounds and intellectual property that it licenses to other drug developers.
NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants ...
The longest government shutdown in U.S. history could logjam drug approvals and clinical tests at the Food and Drug Administration, analysts said Tuesday. Several biotech stocks are at risk.
These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.